Mark Kelley, Melissa Fishel receive $2.4M NCI grant to develop pancreatic cancer treatments

At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylines
There’s “clear evidence that funding is moving and the system is working.”

Tucked in at the end of a 20-minute talk that covered paylines, promising young investigators, and precision medicine, NCI Director Anthony G. Letai beefed up the alliteration with two more words that begin with a “p”: prevention and pilot.

IU Cancer Center Chuckstrong Tailgate Gala raises more than $900,000

The 14th annual Chuckstrong Tailgate Gala raised more than $900,000 for research at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

April 24, 2026

Vol.52 No.16

Clinical

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out.

Cancer Center at Illinois is recognized as NCI Basic Cancer Center, becoming the first new institution to earn this designation in 40 years

The Cancer Center at Illinois was designated as a Basic Cancer Center by NCI.

April 17, 2026

Vol.52 No.15

Clinical Roundup

Experimental drug doubles one-year survival in pancreatic cancer trial, Northwestern study finds

Patients with pancreatic cancer who received the experimental drug elraglusib, alongside standard chemotherapy, were twice as likely to be alive after one year of treatment, compared to those receiving chemotherapy alone, according to the results of a randomized phase II clinical trial conducted by researchers at Northwestern University. The drug also reduced the risk of death by 38%.

April 17, 2026

Vol.52 No.15

Podcast

NCI Director Letai wants you to know: Grant money is flowing again post-government shutdown

The Cancer Letter’s most recent cover story featured an in-depth Q&A with Anthony G Letai, director of the National Cancer Institute.

April 15, 2026

Mark Kelley, Melissa Fishel receive $2.4M NCI grant to develop pancreatic cancer treatments

YOU MAY BE INTERESTED IN

At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylines
There’s “clear evidence that funding is moving and the system is working.”

IU Cancer Center Chuckstrong Tailgate Gala raises more than $900,000

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Cancer Center at Illinois is recognized as NCI Basic Cancer Center, becoming the first new institution to earn this designation in 40 years

Experimental drug doubles one-year survival in pancreatic cancer trial, Northwestern study finds

NCI Director Letai wants you to know: Grant money is flowing again post-government shutdown

Renew today!

Subscriber content

Never miss an issue!

Login

Mark Kelley, Melissa Fishel receive $2.4M NCI grant to develop pancreatic cancer treatments

YOU MAY BE INTERESTED IN

At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylinesThere’s “clear evidence that funding is moving and the system is working.”

IU Cancer Center Chuckstrong Tailgate Gala raises more than $900,000

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OSPanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Cancer Center at Illinois is recognized as NCI Basic Cancer Center, becoming the first new institution to earn this designation in 40 years

Experimental drug doubles one-year survival in pancreatic cancer trial, Northwestern study finds

NCI Director Letai wants you to know: Grant money is flowing again post-government shutdown

Never miss an issue!

Login

At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylines
There’s “clear evidence that funding is moving and the system is working.”

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”